Arcutis Biotherapeutics
ARQT
269 hedge funds and large institutions have $3.11B invested in Arcutis Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 104 increasing their positions, 87 reducing their positions, and 46 closing their positions.
337% more call options, than puts
Call options by funds: $9.97M | Put options by funds: $2.28M
20% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 87
1.17% more ownership
Funds ownership: 105.4% → 106.57% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less funds holding
Funds holding: 282 → 269 (-13)
13% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 46
17% less capital invested
Capital invested by funds: $3.75B → $3.11B (-$632M)
Top Buyers
| 1 |
Marshall Wace
London,
United Kingdom
|
+$50.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$20.6M |
| 3 |
Squarepoint
New York
|
+$16.5M |
| 4 |
BAMCO Inc
New York
|
+$14.5M |
| 5 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
+$14.2M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$45.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.3M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$16.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.8M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$12.3M |
ARQT Hedge Fund Activity: Q1 2026 in Review
269 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2026, worth a combined $3.11B — down 17% from $3.75B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of ARQT and 40 opened new positions — a net loss of 6 holders — while 87 trimmed existing stakes and 104 added.
The largest buyer was Marshall Wace, adding an estimated $50.5M. The largest seller was Jennison Associates, cutting an estimated $45.4M.
- 269 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2026, down from 282 in Q4 2025.
- Funds reported $3.11B of Arcutis Biotherapeutics stock for Q1 2026, down 17% quarter-over-quarter.
- 40 funds opened new Arcutis Biotherapeutics positions in Q1 2026 and 46 closed out, a net change of -6 holders.
- The largest Arcutis Biotherapeutics buyer in Q1 2026 was Marshall Wace, an estimated $50.5M added.
- The largest Arcutis Biotherapeutics seller in Q1 2026 was Jennison Associates, an estimated $45.4M sold.
Based on aggregated 13F filings for Q1 2026.